About Us

Welcome to Tiziana Life Sciences PLC

Founded in 2013, Tiziana Life Sciences plc is a UK AIM-listed biotechnology company (AIM:TILS) focused on developing next generation therapeutics and diagnostics for cancers and immune diseases.

​We combine field-leading medical scientists, providing deep knowledge and novel insights into disease mechanisms, together with a highly experienced clinical development team, to advance potential solutions to tackle these challenging, high-potential opportunities.

Our Mission

INTRODUCTION

Tiziana Life Sciences’ mission is to discover and develop novel molecules that impact serious human diseases in the area of oncology and immunology.

The company has expanded its pipeline of assets to include lead clinical stage development therapeutic candidates in both oncology and immunology and a drug discovery pipeline of small molecule NCEs.

The business employs a lean and virtual R&D business model using highly experienced teams of experts for each business function to maximize value accretion and focus capital on the drug development and discovery processes.

CLINICAL PROGRAMMES

Milciclib
TZLS-201, formerly PHA-848125AC

The Company’s lead compound, acquired from Nerviano Medical Sciences, is an orally bioavailable, small molecule pan-inhibitor of cyclin-dependent kinases (CDK: 1, 2, 4, 5, and 7) as well as Src family kinases.[1-4]

The compound was well tolerated by patients with thymoma in Phase I and Phase 2 clinical trials. Interim data analysis from the Phase 2 trial indicated that the treatment was well-tolerated and it produced encouraging clinical responses. In another study, milciclib in combination with gemcitabine was found to be well tolerated, and the treatment improved clinical outcomes in patients with refractory solid tumors.[5]

A unique feature of milciclib is its ability to reduce microRNAs miR-221 and miR-222. These microRNAs are consistently upregulated in hepatocellular carcinoma (HCC) patients and might contribute towards resistance to treatment with sorafenib. Thus, we believe milciclib has potential to be developed as a drug candidate for treatment of HCC either as a monotherapy or in combination with sorafenib.

Our strategy is to first initiate clinical studies as a Phase 2a monotherapy with milciclib, which will be followed immediately by a Phase 2b clinical study in combination with sorafenib.

References

  1. Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG, et al. Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol Cancer Ther. 2010;9(8):2243-54. [PMID: 20682657]
  2. Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, Cervi G, et al. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-py razolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009;52(16):5152-63. [PMID: 19603809]
  3. Degrassi A, Russo M, Nanni C, Patton V, Alzani R, Giusti AM, et al. Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D) LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging. Mol Cancer Ther. 2010;9(3):673-81. [PMID: 20197397]
  4. Weiss GJ, Hidalgo M, Borad MJ, Laheru D, Tibes R, Ramanathan RK, et al. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2012;30(6):2334-43. [PMID: 22160853]
  5. Aspeslagh S, Shailubhai K, Bahleda R, Reni M and Soria J-C. Phase I dose escalation of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Therapy and Pharmacol. 2017 (in press).

Foralumab
TZLS-401, formerly NI-0401

Foralumab is the only fully human monoclonal anti-CD3 monoclonal antibody (mAb) in clinical development in contrast to the previous non-human or humanized anti-CD3 mABs. Recent data from studies conducted in the laboratories of Prof. Howard Weiner (Harvard University)[1] and Prof. Kevan Herold (Yale University) suggest that oral administration of formalumab has the potential to improve efficacy while minimizing toxicity in the treatment of inflammatory diseases such as NASH (nonalcoholic steatohepatitis), PBS (primary biliary cholangitis) and other autoimmune and inflammatory diseases.

Results from a previous Phase 1 evaluation of foralumab administered via intravenous injection in patients with Crohn’s disease demonstrated foralumab’s immunomodulatory activity in humans.[2] Importantly, recent clinical studies conducted by Prof. Yaron Ilan with oral administration of anti-CD3 (OKT3; murine mAb) in hepatitis C virus infected patients[3] and in NASH patients[4] suggested that the treatment was well-tolerated and produced immunologic effects consistent with potential clinical benefits.

Our strategy is to build on these exciting findings to develop foralumab for treatment of NASH, PBC and other liver diseases. Foralumab may also be combined TZLS-501, a fully human anti-IL-6R mAB, for treatment of rheumatoid arthritis and other diseases.

References

  1. Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016;8(8):889-906. [PMID: 27161438]
  2. van der Woude CJ, Stokkers P, van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L, et al. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. Inflamm Bowel Dis. 2010;16(10):1708-16. [PMID: 20848453]
  3. Halota W, Ferenci P, Kozielewicz D, Dybowska D, Lisovoder N, Samira S, et al. Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial. Journal of viral hepatitis. 2015;22(8):651-7. [PMID: 25412903]
  4. Lalazar G1, Mizrahi M, Turgeman I, Adar T, Ben Ya'acov A, Shabat Y, Nimer A, Hemed N, Zolotarovya L, Lichtenstein Y, Lisovoder N, Samira S, Shalit I, Ellis R, Ilan Y. Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial. J Clin Immunol. 2015 May;35(4):399-407. [PMID: 25876706]

PRE-CLINICAL PROGRAMMES

Anti IL-6R mAb
TZLS-501, formerly NI-1201

Recently acquired anti IL-6R mAb is a fully human monoclonal antibody targeting the interleukin-6 receptor (IL-6R). Anti IL-6R mAb offers a unique mechanism of action in which, it binds to both the membrane-bound and soluble forms of the IL-6R and depletes circulating levels of the IL-6 in the blood. An excessive production of IL-6 is regarded as a key driver of chronic inflammation, associated with autoimmune diseases such as multiple myeloma and rheumatoid arthritis.

Due to its novel mechanism of action, the anti IL-6R mAb, TZLS-501, demonstrates a decreased potential for adverse events and shows superiority, overcoming the limitations of other IL-6 pathway drugs, tocilizumab (Acterma®) and sarilumab (Regeneron and Sanofi). Tiziana’s anti-IL-6R mAb has a higher affinity for the soluble IL-6 receptor demonstrating the potential of being efficacious at blocking IL-6 signaling in conditions of elevated IL-6.

StemPrintER™

StemPrintER™ is a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. This in-vitro prognostic test will be used in conjunction with clinical evaluation to identify those patients at increased risk for early and/or late metastasis. StemPrintER™ will help physicians distinguish ER+/HER2 negative patients:

  1. with a high risk of early recurrence (<5 years) who could benefit from chemotherapy in addition to hormonal therapy
  2. with a high risk of late recurrence who could benefit from prolonged endocrine treatment up to 10 years
  3. with a low risk of early recurrence who might be spared chemotherapy or be eligible for less aggressive treatments

Our diagnostic has a unique biological basis, being based on the detection of cancer stem cell markers, uses a reliable platform (qRT-PCR, FFPE), and has been evaluated in an initial retrospective validation study using a consecutive cohort of approximately 2400 patients with breast cancer. The development team is preparing for a retrospective validation study using an independent cohort and has discussed submission plans with the FDA.

AIM:TILS

Listed on UK Aim Market

2013

First founded

2014

Listed on AIM

Our Team

Tiziana Life Science's Leadership

We combine industry-seasoned management with field-leading medical scientists in immunology and oncology, and a highly experienced clinical development team. Through our combined deep knowledge and novel insights into disease mechanisms and ability to advance potential solutions, our aim is to bring to market therapies that can tackle some of the most challenging disease areas.

The business employs a lean and virtual R&D business model to maximize value accretion and focus capital on the drug development and discovery processes.

Board

Gabriele Cerrone

Gabriele Cerrone

Executive Chairman

Mr Cerrone has a successful track record and extensive experience in the financing and restructuring of micro-cap biotechnology companies.  He has founded nine biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has taken six of these companies to the NASDAQ Market and one to the AIM Market in London.  Mr Cerrone co-founded Trovagene, Inc. (NASDAQ: TROV), a molecular diagnostic company and served as its Co-Chairman; he was a co-founder and served as Chairman of both Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) and Callisto Pharmaceuticals, Inc. (OTCMKTS: CLSP), and was a Director of and led the restructuring of Siga Technologies, Inc. (NASDAQ: SIGA).  Mr Cerrone also co-founded FermaVir Pharmaceuticals, Inc. and served as Chairman of the Board until its merger in September 2007 with Inhibitex, Inc.  Mr Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myers Squibb Co in 2012.​

Mr Cerrone is the Executive Chairman and Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused on oncology using microRNA technology; Chairman and Founder of Tiziana Life Sciences plc (AIM: TILS) an oncology focused therapeutics company; Chairman and Co-Founder of Rasna Therapeutics Limited, a company focused on the development of therapeutics for leukaemias; Co-Founder of ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV); and founder of BioVitas Capital Ltd.

Ricardo Dalla-Favera MD

Ricardo Dalla-Favera MD

Non-Executive Director

Dr Riccardo Dalla-Favera obtained his MD from the University of Milan, Italy in 1976. Following his residency in Haematology Dr Dalla-Favera joined the National Cancer Institute of USA as a visiting fellow. He joined the New York University of Medicine as an assistant Professor in 1983 and then moved to Columbia University College of Physicians and Surgeons in 1991. Here he helped to found the Institute for Cancer Genetics and has been its’ Director since 1999. ​

Dr Dalla-Favera was a Director of the Herbert Irving Comprehensive Cancer Centre (HICCC) from 2005 to 2011 and the Percy and Joanne Uris Professor of Pathology and Genetics & Development. He served as the Chair of the Scientific Advisory Board of the Yale Cancer Centre. He served as the Co-Chair of the National Centre Institute Program Review Group for Leukaemia, Lymphoma and Myeloma, as a member of the Board of Scientific Counsellors of the National Institute of Environmental Health and of the National Cancer Institute. He has been a Member of Scientific Advisory Board at TrovaGene, Inc., since April 2010. He serves as a Member of Scientific Advisory Board at Xigen SA. He serves as a Member of Scientific Advisory Board at Cancer Genetics, Inc. and served as its Director till 2011. Dr Dalla-Favera served as a Director of Callisto Pharmaceuticals Inc. from June 30, 2005 to April 15, 2011. He served as a Director at Synergy Pharmaceuticals, Inc. until April 2011. ​

Dr Dalla-Favera has been a leader in the field of molecular oncology and has made fundamental contributions to the field of cancer, especially in the study of the molecular genetics of B cell malignancies. As a researcher, he has contributed much of the current knowledge on the genetic lesions responsible for human B cell lymphoma, which have led to the development of diagnostic tests and are being tested as targets in clinical trials with lymphoma patients. His has been awarded numerous prizes for his research including the 2007 William Dameshek Prize from the American Society of Hematology, The 2009 San Salvatore Foundation Prize for Outstanding Achievements in Lymphoma Research, and the 2014 Oncomed Giants of Cancer Care Award. He is an elected member of Institute of Medicine of The National Academy of Sciences, USA.

Willy Simon

Willy Simon

Non-Executive Director

Willy Jules Simon is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. From 2004 until 2012, he served as a non-executive director of Redi & Partners Ltd., a fund of funds. He was previously chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2015 and had been a director of Playlogic Entertainment Inc., a NASDAQ OTC listed company.

Kunwar Shailubhai PhD

Kunwar Shailubhai PhD

Executive Director

Kunwar Shailubhai, Ph.D., M.B.A. serves as Chief Executive Officer and Chief Scientific Officer of Tiziana Life Sciences, and is also an Executive Director of the Company. Dr. Shailubhai brings more than 25 years of experience within the life science industry, combined with a distinguished track record of success in translating drugs from concept through commercialisation to market. He also currently serves as CEO of Rasna Therapeutics, Inc., a developer of therapeutics  to address the high unmet need that exists for AML and other forms of leukemia. 

Dr. Shailubhai has been serving as a member of board of Tiziana Life Sciences since 2015. He actively played key roles in development of growth strategies through several key licensings of technologies and drug candidates. Dr. Shailubhai steered the company through prioritisation of projects to focus on novel drug candidates for treatment of autoimmune and inflammatory diseases and cancer.

As co-founder, EVP and CSO of Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) he led the non-clinical, CMC and clinical development of Trulance™ from inception to approval by the FDA, having co-invented and pioneered Synergy’s platform technology for functional GI disorders, inflammatory bowel disease, GI cancer and other human diseases.  Dr. Shailubhai as the chief architect of the IP estate, directed all aspects of IP management, including timely submission of patent applications, directing office actions and coordinating with IP attorneys.

Earlier, from 2003 until 2008, Dr. Shailubhai served as Senior Vice President, Drug Discovery and from 2001 to 2003, he held the position of Vice President, Drug Discovery at Synergy, where he pioneered therapeutic applications of GC-C agonists in a variety of human diseases such as Asthma, COPD and cholesterol lowering.

Prior to Synergy, he was with Monsanto Company, serving as Group Leader, Cancer Prevention and previously served as a Senior Staff Fellow at the National Institutes of Health, and as an Assistant Professor at the University of Maryland.

Dr. Shailubhai received his Ph.D. in microbiology from the University of Baroda, India, and his MBA from the University of Missouri, St. Louis. He has more than 20 issued patents and over 50 peer-reviewed publications.

Leopoldo Zambeletti

Leopoldo Zambeletti

Non-Executive Director

Mr. Zambeletti is an independent strategic advisor in the Healthcare sector. He started his career at KPMG as an auditor followed by a successful career as an investment banker, having led the European and MENA Healthcare Investment Banking teams at JP Morgan and Credit Suisse for a combined total of 19 years. As an independent advisor, he advises life science companies on merger and acquisitions, out-licensing deals and financing strategy.​

He is a non-executive director of, Qardio Inc., Summit Therapeutics plc, Nogra Pharma Limited, Faron Pharmaceuticals OY, DS Biopharma Limited, Afimmune Ltd. and Overjoy Srl. Until recently he served as advisor and Board member to Advanced Accelerator Applications and trustee to Barts and the London Charity. He is the founder of the cultural initiative 5x5 Italy.​

In addition to acting as a non-executive director, Mr Zambeletti will chair the Nomination Committee. He is also a member of the Remuneration Committee and Audit, Risk and Disclosure Committee.​

Mr. Zambeletti received a B.A. in Business from Bocconi University in Milan, Italy.

Executive Leadership

Kunwar Shailubhai PhD

Kunwar Shailubhai PhD

CEO & CSO

Kunwar Shailubhai, Ph.D., M.B.A. serves as Chief Executive Officer and Chief Scientific Officer of Tiziana Life Sciences, and is also an Executive Director of the Company. Dr. Shailubhai brings more than 25 years of experience within the life science industry, combined with a distinguished track record of success in translating drugs from concept through commercialisation to market. He also currently serves as CEO of Rasna Therapeutics, Inc., a developer of therapeutics  to address the high unmet need that exists for AML and other forms of leukemia. 

Dr. Shailubhai has been serving as a member of board of Tiziana Life Sciences since 2015. He actively played key roles in development of growth strategies through several key licensings of technologies and drug candidates. Dr. Shailubhai steered the company through prioritisation of projects to focus on novel drug candidates for treatment of autoimmune and inflammatory diseases and cancer.

As co-founder, EVP and CSO of Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) he led the non-clinical, CMC and clinical development of Trulance™ from inception to approval by the FDA, having co-invented and pioneered Synergy’s platform technology for functional GI disorders, inflammatory bowel disease, GI cancer and other human diseases.  Dr. Shailubhai as the chief architect of the IP estate, directed all aspects of IP management, including timely submission of patent applications, directing office actions and coordinating with IP attorneys.

Earlier, from 2003 until 2008, Dr. Shailubhai served as Senior Vice President, Drug Discovery and from 2001 to 2003, he held the position of Vice President, Drug Discovery at Synergy, where he pioneered therapeutic applications of GC-C agonists in a variety of human diseases such as Asthma, COPD and cholesterol lowering.

Prior to Synergy, he was with Monsanto Company, serving as Group Leader, Cancer Prevention and previously served as a Senior Staff Fellow at the National Institutes of Health, and as an Assistant Professor at the University of Maryland.

Dr. Shailubhai received his Ph.D. in microbiology from the University of Baroda, India, and his MBA from the University of Missouri, St. Louis. He has more than 20 issued patents and over 50 peer-reviewed publications.

Tiziano Lazzaretti

Tiziano Lazzaretti

Chief Financial Officer

Mr Lazzaretti has extensive experience in the healthcare and pharmaceutical industry and joined Tiziana from Pharmentis Srl, a spin-off from Teva Ratiopharm, where he served as Group Finance Director from 2011. Prior to this, Mr Lazzaretti was Executive Director at Alliance Boots Healthcare, and held senior positions at Accenture, SNIA Spa and Fiat Group. ​

Mr Lazzaretti has a Bachelor of Science (BSc Hons) in Accounting and Finance from the University of Turin, Italy, was awarded a Master in Business Administration (MBA) from Bocconi University, Milan and studied Corporate Finance at the London Business School.

Senior Management

Fayez Hamzeh MD, PhD

Fayez Hamzeh MD, PhD

Senior Vice President Clinical Development

Before joining Tiziana Life Sciences, Dr. Fayez Hamzeh served as Head of Clinical Trials Planning and Implementation Strategy of Immunology and Infectious Diseases at Roche Innovation Center, New York from 2015 to 2017. During this period Dr. Hamzeh’s focus was Phase I and Phase II clinical trials in immunology, hepatology and infectious diseases. Dr. Hamzeh served as a Group Medical Director and Head of Infectious Disease, Transplantation and Hepatology at Genentech Inc, South San Francisco from 2009 through 2011 and 2013 through 2015. Dr. Hamzeh served as a Group Medical Director in Genentech Medical Affairs and was responsible for glioblastoma and avastin pan tumor indications. Dr. Hamzeh served as Sr. Medical Director of Hepatology, Transplantation and Infectious Diseases at Roche Pharmaceutical, Nutley NJ from 2003 through 2009. During this period, Dr. Hamzeh was responsible for clinical trials in virology focusing on anti-HIV, anti-influenza, anti-cytomegalovirus, anti-HCV and anti-HBV drugs. Prior to joining the industry in 2003, Dr. Hamzeh served as an Assistant professor of Medicine and Pharmacology and Molecular Therapeutics at Johns Hopkins School of Medicine, Baltimore MD.

During his academic and industry career, Dr. Hamzeh served on many National Institute of Health scientific steering committees including, AIDS Clinical Trials Group, AIDS Malignancy Consortium, Hepatitis-C (HALT-C) Scientific Steering Committee. Dr. Hamzeh received his MD degree in 1981 from the University of Jordan Medical School and his PhD from Johns Hopkins School of Medicine in 1990.  

Jules Jacob

Jules Jacob

Senior Director of Chemistry, Manufacturing, Controls & Non-Clinical Development

Jules Jacob has 30 years of drug development experience and was previously Senior Director, Product Development at Aprecia Pharmaceuticals where he headed development of Spritam®, the first FDA-approved dosage form manufactured using 3-Dimensional Printing and other 505(b)(2) pipeline products. Prior to that Mr. Jacob was Director of Formulation Development at Panacos Pharmaceuticals, developing first-in-class maturation inhibitors for treatment of HIV and Director of Research and Development and Director of Technology Development at Spherics Pharmaceuticals developing bioadhesive dosage forms for treatment of CNS disorders, following the 505 (b)(2) regulatory pathway. 

Mr. Jacob holds over 30 issued patents (US and international) and 38 US patent applications in the fields of drug delivery (proteins, peptides, DNA), nanoencapsulation, microencapsulation, solid oral dosage formulation, polymer compositions, gene therapy, tumor immunotherapy, protein micronization and formulation, imaging and bioadhesion. He has authored more than 30 scientific articles and book chapters and was Grand Award winner of the 2005 Eurand-CRS sponsored “Novel Approaches in Industrial Oral Drug Delivery Award”.  Mr. Jacob completed his undergraduate degree and graduate education in biological and medical sciences at Brown University and has an active visiting faculty appointment in the Department of Molecular Pharmacolgy, Physiology and Biotechnology at Brown.

E. Priya Eddy PhD DABT

E. Priya Eddy PhD DABT

Senior Director, Safety & Toxicology

Dr. Eddy has over 20 years of experience in drug discovery and development. Prior to joining Tiziana, Dr. Eddy served as Senior Director, Toxicology and Safety Pharmacology at Synergy Pharmaceuticals Inc. and was responsible for toxicology, ADME/PK and safety pharmacology studies to support NDA submission of dolcanatide. She also contributed to the NDA for Trulance™. Her work at Synergy also included the development of a delayed release formulation for dolcanatide and she was involved in the supply of API for GLP and feasibility studies.

Prior to Synergy, Dr. Eddy worked at SmithKline Beecham, Millennium Pharmaceuticals and Endo Pharmaceuticals in the areas of drug discovery and development including early clinical development. She received her Ph.D. degree in Biochemistry and is a board certified toxicologist of the American Board of Toxicology. Before joining the pharmaceutical industry she worked at Case Western Reserve University, Cleveland OH in the area of chemical carcinogenesis and environmental health sciences.

Vaseem A Palejwala PhD

Vaseem A Palejwala PhD

Director, Non-Clinical Studies

Dr. Palejwala has 18 years of experience in drug discovery and development. Since 2012, Dr. Palejwala served as Director of Discovery and Preclinical Research at Synergy Pharmaceuticals Inc. where he actively contributed to establishing preclinical animal models for testing therapeutic efficacy and mechanism of action of plecanatide (Trulance™) and dolcanatide in the gastrointestinal tract. He also prepared the preclinical pharmacology section of NDA for Trulance™.

From 2001 - 2012, Dr. Palejwala served as Discovery Scientist/Manager at Sanofi Pharmaceuticals contributing to advancing small molecule and biologic programs in immunology, inflammation, oncology, CNS and metabolic disorders. He contributed to establishing and managing high throughput gene expression profiling platform capabilities at Sanofi and collaborated/contributed in cross-cultural/cross-functional team settings.

Dr. Palejwala received his Ph.D. degree in Microbiology from the M. S. University of Baroda in India and post-doctoral training in Molecular Genetics at the University of Medicine and Dentistry in New Jersey.

Scientific Advisors

Howard Weiner MD

Howard Weiner MD

Harvard Medical School

Dr. Howard Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis (MS) Center and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital in Boston. The Partners MS Center is the first integrated MS Center that combines clinical care, MRI imaging and immune monitoring to the MS patient as part of the 2000 patient CLIMB cohort study. He has pioneered immunotherapy in MS and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer's disease, amyotrophic lateral sclerosis, stroke and brain tumours. He has also pioneered the investigation of the mucosal immune system for the treatment of autoimmune and other diseases and the use of anti-CD3 to induce regulatory T cells for the treatment of these diseases.

Kevan Herold MD

Kevan Herold MD

Yale University

Dr. Kevan Herold is Professor of Immunobiology and of Medicine (Endocrinology) as well as Deputy Director, Yale Center for Clinical Investigation, Director of the Yale Diabetes Center and Director of the TrialNet Center at Yale. His investigative work has focused on developing new ways to prevent and treat autoimmune diseases, using novel translational immunologic and metabolic approaches to prevent progression, in particular anti-CD3 monoclonal antibody therapy. His clinical interests are in the management of endocrine diseases, and he is involved in a number of national and international clinical studies of new treatments.

Thomas Adams PhD

Thomas Adams PhD

Chairman of TrovaGene, Inc

Dr Thomas Adams has been a Director of Synergy Pharmaceuticals since July 2008 and is also the Chairman of TrovaGene, Inc. Dr Adams currently serves as a director of La Jolla Pharmaceutical Co. a publicly held company that develops and markets novel therapeutics for antibody-mediated autoimmune diseases. Since June 2005, Dr Adams has served as a director of IRIS International, Inc., a diagnostics company, and as Chief Technology Officer of IRIS since April 2006. Dr Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006, when Leucadia was acquired by IRIS. In 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside.

Arun Sanyal MD

Arun Sanyal MD

Virginia Commonwealth University

  • Charles Caravati Distinguished Professor and Chair, Division of Gastroenterology, Hepatology and Nutrition at Virginia Commonwealth University School of Medicine​
  • World leader in the field of liver disease
Napoleone Ferrara MD

Napoleone Ferrara MD

UC San Diego

Dr Ferrara is Senior Deputy Director for Basic Sciences at University of California's Moores Cancer Center in San Diego; and Distinguished Professor of Pathology at the University of California's School of Medicine, also in San Diego. Dr Ferrara's research led to the development of the anti-VEGF monoclonal antibody bevacizumab (Avastin®) which was initially approved for the treatment of colorectal cancers, now one of the top ten selling global pharmaceutical products and won the 2010 Lasker Award for his work on VEGF.

Alessandro Padova PhD

Alessandro Padova PhD

CEO, Ri.MED Foundation